Elliott M. Levy
Senior Vice President, Global Development
Amgen
Austria
Biography
Elliott M. Levy, M.D., is senior vice president, Global Development, responsible for the clinical development of Amgen’s pipeline. Before joining Amgen, Levy served as senior vice president and head of Specialty Development at Bristol-Myers Squibb (BMS). Prior to that role, he held the position of senior vice president of Global Pharmacovigilance and Epidemiology. Levy joined BMS in 1997 and during his 17 years at the company, he held a range of senior positions in cardiovascular clinical development, immunoscience clinical research, and global clinical research operations. Prior to BMS, Levy was a member of the Renal Division at Brigham and Women's Hospital in Boston, Massachusetts, where he was an investigator in federally sponsored outcomes research as well as industry-sponsored clinical trials. Levy is a graduate of the Yale School of Medicine, where he was chief medical resident and trained in internal medicine and nephrology. He completed fellowship training in clinical research through the Robert Wood Johnson Clinical Scholars Program at Yale. Elliott M. Levy, M.D., is senior vice president, Global Development, responsible for the clinical development of Amgen’s pipeline. Before joining Amgen, Levy served as senior vice president and head of Specialty Development at Bristol-Myers Squibb (BMS). Prior to that role, he held the position of senior vice president of Global Pharmacovigilance and Epidemiology. Levy joined BMS in 1997 and during his 17 years at the company, he held a range of senior positions in cardiovascular clinical development, immunoscience clinical research, and global clinical research operations. Prior to BMS, Levy was a member of the Renal Division at Brigham and Women's Hospital in Boston, Massachusetts, where he was an investigator in federally sponsored outcomes research as well as industry-sponsored clinical trials. Levy is a graduate of the Yale School of Medicine, where he was chief medical resident and trained in internal medicine and nephrology. He completed fellowship training in clinical research through the Robert Wood Johnson Clinical Scholars Program at Yale.
Research Interest
pharma
